The Utility of Hyperthermic Intraperitoneal Chemotherapy
Valerie Francescutti, MD, FRCSC, assistant professor, Surgical Oncology, Roswell Park Cancer Institute (RPCI), discusses the utility of hyperthermic intraperitoneal chemotherapy (HIPEC).
Clinical Pearls
Valerie Francescutti, MD, FRCSC, assistant professor, Surgical Oncology, Roswell Park Cancer Institute (RPCI), discusses the utility of hyperthermic intraperitoneal chemotherapy (HIPEC).
- HIPEC involves removing all cancer from a patient’s abdominal cavity and providing heated chemotherapy for the management of any microscopic tumors
- Indications for HIPEC include colorectal cancer that has resulted in peritoneal metastases, appendiceal cancer, and peritoneal mesothelioma
- At RPCI, 50-60% of patients treated with HIPEC have appendiceal or colorectal cancers
Recent Videos
Related Content
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Article
Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
